Advertisement

Building Resiliency through Cognitive Reappraisal and Lifestyle Modification (December 2022)

December 05, 2022 - January 16, 2023 | Virtual Conference

Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Annual Conference & Exhibits

March 29 - April 01, 2023 | Montreal, QC, Canada

Liver Cancer Summit 2023

April 20-22, 2023 | Estoril, Portugal

Multidisciplinary NET Medical Symposium 2023

October 05-07, 2023 | Montréal, QC, Canada

Multidisciplinary NET Medical Symposium 2024

October 12-14, 2024 | Chicago, IL, United States

Advertisement

Advertisement

Etrolizumab vs. infliximab for moderate to severely active ulcerative colitis treatment (GARDENIA)

The Lancet: Gastroenterology & Hepatology

Intensive versus standard drug therapy for symptomatic Crohn's disease strictures (STRIDENT)

The Lancet: Gastroenterology & Hepatology

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST)

The Lancet: Gastroenterology & Hepatology

AJM300 (carotegrast methyl), an oral alpha4-integrin antagonist, for patients with moderate ulcerative colitis: a phase 3 trial

The Lancet: Gastroenterology & Hepatology

Statin use and reduced hepatocellular carcinoma risk in patients with non- alcoholic fatty liver disease

Clinical Gastroenterology and Hepatology

Guselkumab for the treatment of Crohn disease: Induction results from the phase 2 GALAXI-1 study

Gastroenterology

Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)

Diabetes, Obesity and Metabolism

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: A randomized, open-label, phase 2 trial

The Lancet: Gastroenterology & Hepatology

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: A single-arm, open-label, phase 2 trial

The Lancet: Gastroenterology & Hepatology

Rectal indomethacin to prevent pancreatitis after extracorporeal shock wave lithotripsy (RIPEP): A single-center, double-blind, randomized, placebo-controlled trial

The Lancet: Gastroenterology & Hepatology

Advertisement